Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated)

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated)
DrugBank Accession Number
DB11044
Background

A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the "flu shot", is a vaccine that protects against infection from the influenza viruses. Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen". This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. Upon re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it was previously exposed to.

There are two basic types of vaccines available: inactivated influenza vaccine (IIV) and live attenuated influenza vaccine (LAIV). Inactivated vaccines contain a virus particle that has been grown in media and then subsequently killed, or inactivated, through exposure to heat or chemicals such as formaldehyde 3. Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques. Live vaccines maintain their replicative ability.

Type
Biotech
Groups
Approved
Biologic Classification
Vaccines
Inactivated
Synonyms
Not Available

Pharmacology

Indication

Not Available

Pharmacology
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Contraindications
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Adverseeffects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbataceptThe therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) can be decreased when used in combination with Abatacept.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) is combined with Acetylsalicylic acid.
AdalimumabThe therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) can be decreased when used in combination with Adalimumab.
AldesleukinThe therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) can be decreased when used in combination with Aldesleukin.
AlefaceptThe therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) can be decreased when used in combination with Alefacept.
AlemtuzumabThe therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) can be decreased when used in combination with Alemtuzumab.
AltretamineThe therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) can be decreased when used in combination with Altretamine.
Aminosalicylic acidThe risk or severity of adverse effects can be increased when Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) is combined with Aminosalicylic acid.
AmsacrineThe therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) can be decreased when used in combination with Amsacrine.
AnakinraThe therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) can be decreased when used in combination with Anakinra.
Interactions
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Products

Products2
Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Active Moieties
NameKindUNIICASInChI Key
Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated)hemagglutinin45E2IPU4MGNot AvailableNot applicable
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
AfluriaInfluenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) (15 ug/0.5mL) + Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) (15 ug/0.5mL) + Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated) (15 ug/0.5mL)Injection, suspensionIntramuscularCsl Limited2009-07-012010-06-30US flag
AfluriaInfluenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) (7.5 ug/0.25mL) + Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) (7.5 ug/0.25mL) + Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated) (7.5 ug/0.25mL)Injection, suspensionIntramuscularCsl Limited2009-07-012010-06-30US flag
AfluriaInfluenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) (15 ug/0.5mL) + Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated) (15 ug/0.5mL) + Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (propiolactone inactivated) (15 ug/0.5mL)Injection, suspensionIntramuscularCsl Limited2011-07-152012-06-30US flag
AfluriaInfluenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) (15 ug/0.5mL) + Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated) (15 ug/0.5mL) + Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (propiolactone inactivated) (15 ug/0.5mL)Injection, suspensionIntramuscularCsl Limited2010-07-302011-06-30US flag
AfluriaInfluenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) (15 ug/0.5mL) + Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated) (15 ug/0.5mL) + Influenza A virus A/Hong Kong/4801/2014 X-263B (H3N2) antigen (propiolactone inactivated) (15 ug/0.5mL)Injection, suspensionIntramuscularSeqirus Pty Ltd2011-07-152016-06-17US flag
AfluriaInfluenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) (15 ug/0.5mL) + Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated) (15 ug/0.5mL) + Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (propiolactone inactivated) (15 ug/0.5mL)Injection, suspensionIntramuscularCsl Limited2011-07-152012-06-30US flag
AfluriaInfluenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) (15 ug/0.5mL) + Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated) (15 ug/0.5mL) + Influenza A virus A/Hong Kong/4801/2014 X-263B (H3N2) antigen (propiolactone inactivated) (15 ug/0.5mL)Injection, suspensionIntramuscularSeqirus Pty Ltd2011-07-152016-06-17US flag
AfluriaInfluenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) (15 ug/0.5mL) + Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated) (15 ug/0.5mL) + Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (propiolactone inactivated) (15 ug/0.5mL)Injection, suspensionIntramuscularCsl Limited2010-07-302011-06-30US flag
FluvirinInfluenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) (15 ug/0.5mL) + Influenza A virus A/Christchurch/16/2010 NIB-74 (H1N1) antigen (propiolactone inactivated) (15 ug/0.5mL) + Influenza A virus A/Hong Kong/4801/2014 X-263B (H3N2) antigen (propiolactone inactivated) (15 ug/0.5mL)Injection, suspensionIntramuscularSeqirus, Inc.2016-07-012017-06-30US flag
FluvirinInfluenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) (15 ug/0.5mL) + Influenza A virus A/Christchurch/16/2010 NIB-74 (H1N1) antigen (propiolactone inactivated) (15 ug/0.5mL) + Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (propiolactone inactivated) (15 ug/0.5mL)Injection, suspensionIntramuscularNovartis Vaccines And Diagnostics, Inc.2011-07-012012-06-30US flag

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
293LSV29OL
CAS number
Not Available

References

General References
Not Available
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedPreventionFlu caused by Influenza1
4CompletedPreventionInfluenza, Human3
4Enrolling by InvitationTreatmentInfertility1
4Enrolling by InvitationTreatmentInfertility / Recurrent Miscarriages1
3CompletedPreventionFlu caused by Influenza2
1, 2CompletedPreventionAllergy, Egg / Eligible for Vaccination Against Influenza1
Not AvailableActive Not RecruitingNot AvailableFetal Malformation / Influenza, Human / Pregnant State1
Not AvailableCompletedNot AvailableInflammatory Bowel Diseases (IBD)1
Not AvailableCompletedBasic ScienceImmune Responses1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Injection, suspensionIntramuscular
KitTopical
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created on December 01, 2015 20:05 / Updated on June 12, 2020 16:53